ResMed Updates CDI Count Amid Routine Share Transfers, Issuances and Buybacks

The latest update is out from Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh ( (AU:RMD) ).

ResMed Inc. reported its April 2026 CHESS Depositary Interest (CDI) figures, showing a slight decrease in CDIs on issue on the ASX to 564,292,650, largely due to net transfers between CDIs and common stock traded on the NYSE. The company also recorded a net increase in underlying securities and common stock not represented by CDIs, reflecting ongoing share issuance tied to employee equity plans and stock repurchase activity in the U.S. market.

The shift between CDIs and NYSE-listed common stock highlights active capital management and continued use of equity-based compensation, while maintaining flexibility across its dual-listing structure. For ASX investors, the modest net reduction in CDIs and corresponding changes in underlying U.S.-listed shares underscore that movements in ResMed’s capital base are being driven by routine transfers, employee share programs and buybacks rather than major new capital raisings.

The most recent analyst rating on (AU:RMD) stock is a Buy with a A$44.80 price target. To see the full list of analyst forecasts on Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh stock, see the AU:RMD Stock Forecast page.

More about Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh

ResMed Inc. is a medical technology company that develops and sells devices and software for the diagnosis, treatment and management of sleep apnea and other chronic respiratory conditions. The company’s shares are listed on the NYSE, with Australian investors accessing exposure primarily through CHESS Depositary Interests (CDIs) quoted on the ASX.

Average Trading Volume: 1,311,550

Technical Sentiment Signal: Hold

Current Market Cap: A$41.48B

Learn more about RMD stock on TipRanks’ Stock Analysis page.